Nemdatine: Uses, Dosage & Side Effects
An NMDA receptor antagonist for the treatment of moderate to severe Alzheimer’s disease in adults
Nemdatine (memantine hydrochloride) is a prescription medication used to treat moderate to severe Alzheimer’s disease. It belongs to a class of drugs known as NMDA (N-methyl-D-aspartate) receptor antagonists, which work by regulating the activity of glutamate, a chemical messenger involved in learning, memory, and neuronal function. In Alzheimer’s disease, excessive glutamate signaling contributes to neuronal damage and cognitive decline. By blocking pathological NMDA receptor activation while preserving normal signaling, Nemdatine helps slow the progression of symptoms including memory loss, confusion, and difficulties with daily activities. It is available as a 5 mg film-coated tablet and is typically titrated up to a maintenance dose of 20 mg daily over several weeks.
Quick Facts: Nemdatine
Key Takeaways
- Nemdatine (memantine) is indicated for moderate to severe Alzheimer’s disease and works by blocking excessive glutamate activity that damages neurons.
- The dose is gradually increased from 5 mg once daily to 20 mg daily over approximately 3–4 weeks to minimize side effects.
- It can be used alone or in combination with cholinesterase inhibitors (such as donepezil) for potentially additive benefits.
- Common side effects include dizziness, headache, constipation, and drowsiness, which are generally mild and often transient.
- Memantine does not cure Alzheimer’s disease but can help maintain cognitive function and daily activities for longer, slowing the rate of decline.
What Is Nemdatine and What Is It Used For?
Nemdatine is a prescription medication containing the active substance memantine hydrochloride. It is specifically indicated for the treatment of patients with moderate to severe Alzheimer’s disease, the most common form of dementia affecting millions of people worldwide. The World Health Organization estimates that more than 55 million people live with dementia globally, with Alzheimer’s disease accounting for 60–70% of all cases.
Memantine belongs to a pharmacological class known as NMDA (N-methyl-D-aspartate) receptor antagonists. In a healthy brain, glutamate is the primary excitatory neurotransmitter and plays an essential role in learning and memory formation. However, in Alzheimer’s disease, the progressive accumulation of amyloid-beta plaques and neurofibrillary tangles leads to chronically elevated glutamate levels. This excessive glutamate stimulation of NMDA receptors, known as excitotoxicity, causes calcium influx into neurons, leading to oxidative stress, mitochondrial dysfunction, and ultimately neuronal death.
Memantine acts as a moderate-affinity, voltage-dependent, uncompetitive NMDA receptor antagonist. This means that under normal physiological conditions, memantine does not significantly block NMDA receptor function, allowing the receptor signaling needed for learning and memory to proceed. However, when glutamate levels become pathologically elevated — as they do in Alzheimer’s disease — memantine effectively blocks the excessive receptor activation, thereby reducing excitotoxic neuronal damage. This dual action provides both neuroprotective and symptomatic benefits.
Clinical trials have demonstrated that memantine improves or stabilizes cognitive function (as measured by standardized scales such as the Severe Impairment Battery, SIB), global clinical impression (assessed by the Clinician’s Interview-Based Impression of Change, CIBIC-plus), and the ability to perform activities of daily living (measured by the Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory, ADCS-ADL). Importantly, memantine can also have positive effects on behavioral and psychological symptoms of dementia, including agitation, aggression, and irritability.
Nemdatine is intended for use only in patients with moderate to severe Alzheimer’s disease. It is not indicated for mild Alzheimer’s disease, other forms of dementia (such as vascular dementia or Lewy body dementia), or age-related cognitive decline. The diagnosis of Alzheimer’s disease should be established by a qualified physician using internationally recognized diagnostic criteria before initiating treatment with Nemdatine.
What Should You Know Before Taking Nemdatine?
Contraindications
Nemdatine must not be used in patients who are hypersensitive (allergic) to memantine hydrochloride or to any of the excipients listed in the product composition. If you have previously experienced an allergic reaction to memantine or any product containing memantine, do not take Nemdatine. Allergic reactions may include skin rash, swelling, breathing difficulties, or anaphylaxis, and any such reaction requires immediate medical attention.
Warnings and Precautions
Before starting Nemdatine, inform your doctor about all of your medical conditions, particularly if you have or have had any of the following:
- Epilepsy or a history of seizures: Memantine may lower the seizure threshold in some patients. Clinical experience with memantine in patients with active epilepsy is limited, and careful monitoring is recommended.
- Kidney impairment: Memantine is primarily excreted by the kidneys. In patients with moderate to severe renal impairment (creatinine clearance 5–49 mL/min), the dose of memantine should be reduced. Your doctor will determine the appropriate dose based on your kidney function.
- Conditions that raise urine pH: The elimination of memantine is reduced in alkaline urine. Conditions such as renal tubular acidosis, severe urinary tract infections (Proteus bacteria), and strict vegetarian diets can make urine more alkaline, leading to higher memantine levels and a potential increased risk of side effects.
- Recent heart attack, congestive heart failure, or uncontrolled hypertension: Although memantine is not primarily a cardiovascular drug, limited data exist for patients with these conditions. Clinical monitoring is advised.
Memantine should be used with caution in patients with factors predisposing to epilepsy. The concurrent use of other NMDA antagonists (such as amantadine, ketamine, or dextromethorphan) should be avoided as the combination may increase the risk of adverse CNS effects.
Pregnancy and Breastfeeding
The safety of Nemdatine during pregnancy has not been established. Animal reproductive studies have shown potential adverse effects at doses significantly higher than those used in humans. As a precaution, Nemdatine should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether memantine is excreted in human breast milk. Given the lipophilic nature of the molecule and the potential for adverse effects in nursing infants, Nemdatine should not be used during breastfeeding. A decision must be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother.
Driving and Operating Machinery
Moderate to severe Alzheimer’s disease typically impairs driving ability and the capacity to operate machinery. In addition, memantine may cause dizziness and drowsiness in some patients, which could further affect these abilities. The treating physician should individually assess whether the patient is able to continue driving or operating complex machinery while taking Nemdatine.
How Does Nemdatine Interact with Other Drugs?
Drug interactions with memantine are generally manageable, but awareness of potential interactions is essential for safe use. Because memantine is primarily excreted unchanged by the kidneys rather than metabolized by hepatic cytochrome P450 enzymes, the risk of pharmacokinetic interactions with most medications is relatively low. However, several important interactions should be considered.
Major Interactions
The following drug interactions are considered clinically significant and may require dose adjustment, enhanced monitoring, or avoidance of the combination:
| Drug / Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Amantadine | Pharmacodynamic (NMDA antagonist) | Increased risk of CNS adverse effects including confusion, hallucinations, and psychosis | Avoid combination; monitor closely if co-administration is unavoidable |
| Ketamine | Pharmacodynamic (NMDA antagonist) | Risk of additive or synergistic CNS effects, including hallucinations and psychomotor disturbances | Avoid concurrent use |
| Dextromethorphan | Pharmacodynamic (NMDA antagonist) | Potential for additive CNS effects | Use with caution; consider alternatives |
| Urinary alkalinizers (sodium bicarbonate, carbonic anhydrase inhibitors) | Pharmacokinetic (reduced renal elimination) | Elevated memantine plasma levels due to decreased renal clearance in alkaline urine | Monitor for increased side effects; dose reduction may be necessary |
Minor Interactions
The following interactions are generally of lesser clinical significance but should be kept in mind:
| Drug / Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Donepezil, rivastigmine, galantamine (cholinesterase inhibitors) | Pharmacodynamic (complementary mechanisms) | No negative interaction; potential additive clinical benefit | Combination is commonly used and recommended by guidelines |
| L-dopa, dopaminergic agonists | Pharmacodynamic | Memantine may enhance the effects of L-dopa and dopaminergic agents | Monitor for increased dopaminergic effects |
| Hydrochlorothiazide | Pharmacokinetic | Reduced hydrochlorothiazide absorption reported in some studies | Monitor blood pressure; adjust diuretic dose if needed |
| Cimetidine, ranitidine | Pharmacokinetic (shared tubular secretion) | Potential for altered plasma levels of either drug | Monitor for adverse effects; generally no dose adjustment needed |
| Warfarin | Pharmacokinetic | Isolated reports of increased INR values | Monitor INR closely when initiating or changing memantine dose |
| Barbiturates, neuroleptics | Pharmacodynamic | Possible altered pharmacological effects | Clinical monitoring advised |
Memantine is not metabolized by cytochrome P450 (CYP) enzymes, which means it is unlikely to interact with the many medications that are metabolized through this pathway. This favorable pharmacokinetic profile is particularly advantageous in elderly patients who often take multiple medications.
What Is the Correct Dosage of Nemdatine?
Treatment with Nemdatine should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. The dose should be titrated gradually to minimize the risk of adverse effects. The drug should be taken at the same time each day, with or without food.
Adults
The recommended titration schedule for adults with moderate to severe Alzheimer’s disease is as follows:
| Week | Daily Dose | Tablets | Notes |
|---|---|---|---|
| Week 1 | 5 mg | 1 tablet once daily | Starting dose |
| Week 2 | 10 mg | 2 tablets once daily or 1 tablet twice daily | First dose increase |
| Week 3 | 15 mg | 3 tablets once daily or as directed | Second dose increase |
| Week 4 onwards | 20 mg | 4 tablets once daily or as directed | Maintenance dose |
The minimum recommended interval between dose increases is one week. Each dose increase should be evaluated by the treating physician, who should assess tolerability before proceeding to the next dose level. The maximum recommended daily dose is 20 mg.
Children
The safety and efficacy of Nemdatine in children and adolescents below the age of 18 have not been established. Alzheimer’s disease does not occur in the pediatric population, and there is no relevant indication for use in this age group. Nemdatine should not be used in patients under 18 years of age.
Elderly
No dose adjustment is required in elderly patients (aged 65 years and over) with normal kidney function. The recommended titration schedule and maintenance dose are the same as for younger adults. However, given that elderly patients are more susceptible to adverse effects and are more likely to have reduced renal function, careful monitoring is recommended, particularly during the titration phase. Regular assessment of kidney function is advisable to ensure appropriate dosing.
Renal Impairment
Dose Adjustments for Kidney Function
- Mild impairment (CrCl 50–80 mL/min): No dose adjustment necessary.
- Moderate impairment (CrCl 30–49 mL/min): The maintenance dose should be reduced to 10 mg per day. If well tolerated for at least 7 days, the dose may be increased to 20 mg per day according to the standard titration scheme.
- Severe impairment (CrCl 5–29 mL/min): The daily dose should be reduced to 10 mg per day.
Missed Dose
If a dose of Nemdatine is missed, the patient or caregiver should take the next dose at the usual time. A double dose should never be taken to compensate for a missed dose. If multiple consecutive doses have been missed, the prescribing physician should be consulted regarding whether it is necessary to restart the titration schedule, as abrupt changes in memantine levels may temporarily worsen symptoms.
Overdose
In case of a suspected overdose, contact your local poison control center or emergency services immediately. Symptoms of memantine overdose may include restlessness, psychosis, visual hallucinations, drowsiness, stupor, and loss of consciousness. Treatment is symptomatic and supportive. There is no specific antidote for memantine. Standard measures to remove the active substance from the body (gastric lavage, activated charcoal, acidification of urine, forced diuresis) may be considered. In case of overdose with clinical signs, general symptomatic treatment and monitoring in an intensive care unit may be required.
What Are the Side Effects of Nemdatine?
Like all medicines, Nemdatine can cause side effects, although not everybody experiences them. In clinical trials involving thousands of patients, memantine was generally well tolerated. The majority of adverse effects were mild to moderate in intensity and resolved without the need to discontinue treatment. The following side effects have been reported with memantine, grouped by their frequency of occurrence.
Common
May affect up to 1 in 10 people
- Dizziness
- Headache
- Constipation
- Drowsiness (somnolence)
- Elevated blood pressure (hypertension)
- Shortness of breath (dyspnea)
Uncommon
May affect up to 1 in 100 people
- Fatigue
- Fungal infections
- Confusion
- Hallucinations (predominantly in patients with severe Alzheimer’s disease)
- Abnormal gait
- Heart failure
- Venous thrombosis / thromboembolism
Rare
May affect up to 1 in 1,000 people
- Seizures (convulsions)
- Psychotic reactions
Not Known
Frequency cannot be estimated from available data
- Pancreatitis
- Hepatitis
- Depression
- Suicidal ideation
- Stevens-Johnson syndrome
- Agranulocytosis, leukopenia, pancytopenia, thrombocytopenia
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
Alzheimer’s disease itself is associated with depression, suicidal ideation, agitation, and psychotic symptoms. These have also been reported in patients treated with memantine, and it can be difficult to distinguish drug-related effects from symptoms of the underlying disease. Careful clinical assessment is needed to determine the cause of new or worsening psychiatric symptoms.
If you experience any side effects that are persistent, severe, or concerning, speak with your doctor or pharmacist. You should also report any suspected adverse reactions through the national pharmacovigilance reporting system in your country. This helps gather additional information on the safety profile of the medication.
Contact your doctor or emergency services immediately if you experience: severe allergic reactions (swelling of the face, lips, tongue, or throat; difficulty breathing; hives); seizures; signs of Stevens-Johnson syndrome (severe skin reaction with blistering); or symptoms suggesting blood disorders (unexplained fever, sore throat, mouth ulcers, unusual bruising or bleeding).
How Should You Store Nemdatine?
Proper storage of Nemdatine is essential to maintain the safety and efficacy of the medication throughout its shelf life. The film-coated tablets should be stored at a temperature not exceeding 25°C (77°F). Store the tablets in their original blister packaging to protect them from moisture and light. Do not transfer the tablets to a different container unless specifically recommended by your pharmacist.
Keep Nemdatine out of the sight and reach of children. Accidental ingestion by children can cause serious adverse effects and requires immediate medical attention. Consider using a locked medicine cabinet or other secure storage method, particularly in households with young children.
Do not use Nemdatine after the expiry date printed on the blister pack and the outer carton. The expiry date refers to the last day of the indicated month. Do not use the medication if you notice any visible signs of deterioration, such as discoloration, crumbling, or unusual odor.
Unused or expired medicines should not be disposed of via household waste or wastewater. Ask your pharmacist about local drug take-back programs or return schemes to ensure environmentally responsible disposal. Proper disposal of medicines helps protect the environment and prevents accidental exposure.
What Does Nemdatine Contain?
Active Ingredient
The active substance in Nemdatine is memantine hydrochloride. Each film-coated tablet contains 5 mg of memantine hydrochloride, which is equivalent to approximately 4.15 mg of memantine base. Memantine hydrochloride is a white to off-white crystalline powder that is freely soluble in water.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Lactose monohydrate | Filler / Diluent | Contains lactose – patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine |
| Microcrystalline cellulose | Filler / Binder | Provides tablet structure and compressibility |
| Colloidal anhydrous silica | Glidant | Improves powder flow during manufacturing |
| Talc | Glidant / Anti-adherent | Prevents sticking during tablet compression |
| Magnesium stearate | Lubricant | Facilitates tablet ejection from die |
| Opadry II White (film coating) | Film coating | Contains polyvinyl alcohol, titanium dioxide (E171), macrogol, talc |
Appearance and Pack Sizes
Nemdatine 5 mg film-coated tablets are white to off-white, oval-shaped tablets marked with a score line on one side. The score line is intended to facilitate breaking the tablet for ease of swallowing and is not intended for dose division. Nemdatine may be available in blister packs of 28, 30, 56, 98, or 100 tablets. Not all pack sizes may be marketed in every country.
Nemdatine tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication. If you have a known lactose intolerance, discuss alternative formulations with your doctor or pharmacist.
Frequently Asked Questions About Nemdatine
Nemdatine (memantine) is a prescription medication used to treat moderate to severe Alzheimer’s disease. It belongs to a class of drugs called NMDA receptor antagonists and works by regulating glutamate activity in the brain to slow the progression of cognitive and functional decline. It does not cure Alzheimer’s disease but can help maintain daily functioning and cognitive abilities for longer. Nemdatine is not indicated for mild Alzheimer’s disease or other types of dementia.
Nemdatine works by blocking NMDA (N-methyl-D-aspartate) receptors in the brain. In Alzheimer’s disease, excessive glutamate stimulation of these receptors causes excitotoxicity, leading to neuronal damage and cognitive decline. Memantine acts as a moderate-affinity, uncompetitive antagonist that blocks pathological receptor activation while still allowing normal physiological signaling needed for learning and memory. This dual action provides both neuroprotective and symptomatic benefits.
Yes, Nemdatine can be used in combination with cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine. In fact, the combination of memantine with a cholinesterase inhibitor is a commonly recommended treatment strategy for moderate to severe Alzheimer’s disease, as the two drug classes work through different mechanisms and may provide additive benefits. Clinical studies have shown that adding memantine to donepezil can improve cognition, daily functioning, and behavioral symptoms compared to donepezil alone.
The most common side effects of Nemdatine include dizziness, headache, constipation, drowsiness, and elevated blood pressure. These side effects are generally mild to moderate and often resolve as the body adjusts to the medication. Memantine is generally well tolerated compared to many other medications used in dementia. Serious side effects are uncommon but can include hallucinations, confusion, and seizures. Always report any unusual symptoms to your healthcare provider.
Nemdatine is gradually titrated over a period of approximately 3 to 4 weeks, starting at 5 mg once daily and increasing by 5 mg per week until the maintenance dose of 20 mg daily is reached. Some patients and caregivers may notice improvements in attention, daily functioning, or behavioral symptoms within 4 to 12 weeks of reaching the full dose. However, the primary goal of memantine is to slow the rate of decline rather than produce dramatic improvements, so benefits may be more apparent over months of continued treatment.
Nemdatine can be taken with or without food. Food does not significantly affect the absorption of memantine. The tablet should be swallowed whole with water, taken at the same time each day to maintain consistent blood levels. If the patient has difficulty swallowing tablets, the tablet may be dissolved in water, although this should be discussed with a pharmacist or healthcare provider. Consistency in timing is more important than whether it is taken with a meal.
References
- European Medicines Agency (EMA). Memantine – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: EMA Memantine Referral.
- U.S. Food and Drug Administration (FDA). Namenda (memantine hydrochloride) – Prescribing Information. Forest Pharmaceuticals / Allergan. Revised 2024.
- Reisberg B, Doody R, Stöffler A, et al. Memantine in Moderate-to-Severe Alzheimer’s Disease. N Engl J Med. 2003;348(14):1333–1341. doi:10.1056/NEJMoa013128.
- Tariot PN, Farlow MR, Grossberg GT, et al. Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. JAMA. 2004;291(3):317–324. doi:10.1001/jama.291.3.317.
- McShane R, Westby MJ, Roberts E, et al. Memantine for Dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6.
- National Institute for Health and Care Excellence (NICE). Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers. NICE Guideline NG97. Updated 2024.
- Cummings J, Lee G, Nahed P, et al. Alzheimer’s Disease Drug Development Pipeline: 2024. Alzheimers Dement (N Y). 2024;10(1):e12465.
- World Health Organization (WHO). Dementia. Fact Sheet. 2023. Available at: WHO Dementia.
- British National Formulary (BNF). Memantine hydrochloride. National Institute for Health and Care Excellence (NICE). 2025.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2024;20(5):3708–3821.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in neurology, geriatric medicine, and clinical pharmacology with extensive experience in dementia management and NMDA receptor-targeted therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, NICE, AAN).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.